FDAsafety guidance72% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · GLP-1
- Sub-indication
- General
Related signal: Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance